Dennis Serge Metselaar

Dr. Dennis Serge Metselaar

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
MMMichaël H. Meel
Michaël H. Meel
MGMark Cornelis de Gooijer
Mark Cornelis de Gooijer
DMDennis Serge Metselaar
Dennis Serge Metselaar
ASA. Charlotte P. Sewing
A. Charlotte P. Sewing
KZKenn Zwaan
Kenn Zwaan
EHEsther Hulleman
Esther Hulleman
Purpose: Diffuse intrinsic pontine glioma (DIPG) is an incurable type of pediatric brain cancer, which in the majority of cases is driven by mutations in genes encoding histone 3 (H3K27M). We here determined the preclinical therapeutic potential of combined AXL and HDAC inhibition in these tumors to reverse their mesenchymal, therapy-resistant, phenotype. Experimental Design: We used public databases and patient-derived DIPG cells to identify putative drivers of the mesenchymal transition in these tumors. Patient-derived neurospheres, xenografts, and allografts were used to determine the therapeutic potential of combined AXL/HDAC inhibition for the treatment of DIPG. Results: We identified AXL as a therapeutic target and regulator of the mesenchymal transition in DIPG. Combined AXL and HDAC inhibition had a synergistic and selective antitumor effect on H3K27M DIPG cells. Treatment of DIPG cells with the AXL inhibitor BGB324 and the HDAC inhibitor panobinostat resulted in a decreased expression of mesenchymal and stem cell genes. Moreover, this combination treatment decreased expression of DNA damage repair genes in DIPG cells, strongly sensitizing them to radiation. Pharmacokinetic studies showed that BGB324, like panobinostat, crosses the blood–brain barrier. Consequently, treatment of patient-derived DIPG xenograft and murine DIPG allograft-bearing mice with BGB324 and panobinostat resulted in a synergistic antitumor effect and prolonged survival. Conclusions: Combined inhibition of AXL and HDACs in DIPG cells results in a synergistic antitumor effect by reversing their mesenchymal, stem cell-like, therapy-resistant phenotype. As such, this treatment combination may serve as part of a future multimodal therapeutic strategy for DIPG.

3 November 2023 in Cell Reports Medicine
Verified
Journal Article
Open access
ACAimée du Chatinier
Aimée du Chatinier
IVIrene Querol Velilla
Irene Querol Velilla
MMMichaël Hananja Meel
Michaël Hananja Meel
EHEelco Wieger Hoving
Eelco Wieger Hoving
EHEsther Hulleman
Esther Hulleman
DMDennis Serge Metselaar
Dennis Serge Metselaar
Brain tumors are the leading cause of cancer-related mortality in children. Despite the development of immunotherapeutic strategies for adult brain tumors, progress in pediatric neuro-oncology has been hindered by the complex and poorly understood nature of the brain's immune system during early development, a phase that is critical for the onset of many pediatric brain tumors. A defining characteristic of these tumors is the abundance of microglia, the resident immune cells of the central nervous system. In this review, we explore the concept of microglial diversity across brain regions and throughout development and discuss how their maturation stage may contribute to tumor growth in children. We also summarize the current knowledge on the roles of microglia in common pediatric brain tumor entities and provide examples of myeloid-based immunotherapeutic strategies. Our review underscores the importance of microglial plasticity in pediatric brain tumors and its significance for developing effective immunotherapeutic strategies.

4 March 2025 in Cancers
Verified
Journal Article
Open access
PDF file
LKLinde Kampers
Linde Kampers
DMDennis Serge Metselaar
Dennis Serge Metselaar
Maria VinciMaria Vinci
Maria Vinci
FSFabio Scirocchi
Fabio Scirocchi
SZSophie Veldhuijzen van Zanten
Sophie Veldhuijzen van Zanten
SGStefaan W Van Gool
Stefaan W Van Gool
Malignant glioma is a highly aggressive, therapeutically non-responsive, and deadly disease with a unique tumor microenvironment (TME). Of the 14 currently recognized and described cancer hallmarks, five are especially implicated in malignant glioma and targetable with repurposed drugs: cancer stem-like cells, in general, and glioma stem-like cells in particular (GSCs), vascularization and hypoxia, metabolic reprogramming, tumor-promoting inflammation and sustained proliferative signaling. Each hallmark drives malignant glioma development, both individually and through interactions with other hallmarks, in which the TME plays a critical role. To combat the aggressive malignant glioma spatio-temporal heterogeneity driven by TME interactions, and to overcome its therapeutic challenges, a combined treatment strategy including anticancer therapies, repurposed drugs and multimodal immunotherapy should be the aim for future treatment approaches.

25 November 2025 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
ATAntonio Carlos Tallon-Cobos
Antonio Carlos Tallon-Cobos
KVKonstantinos Vazaios
Konstantinos Vazaios
PWPiotr Waranecki
Piotr Waranecki
MHMarliek van Hoesel
Marliek van Hoesel
ACAnnelisa M. Cornel
Annelisa M. Cornel
Esther HullemanEsther Hulleman
Esther Hulleman
Aggressive pediatric brain tumor models of ependymoma are highly sensitive to GD2-directed (CAR T) cell therapy

28 August 2024 in medRxiv
Verified
Preprint
Open access
PDF file
MGMyrthe M.M.R. Griffioen
Myrthe M.M.R. Griffioen
DMDennis Serge Metselaar
Dennis Serge Metselaar
High-grade glioma (HGG) patients have a dismal prognosis, due to a lack of effective treatments. In order to change the fate of HGG patients and decrease the current treatment-related side effects, therapy focus has shifted in the past years to immunotherapy, such as chimeric antigen receptor (CAR)-based treatments. Recent developments in CAR-based therapy show promising results in adult glioma patients, and the first clinical trials for pediatric patients with HGG are in progress. However, there are significant differences between pediatric HGG (pHGG) and their adult counterparts, including the composition of the tumor immune microenvironment (TIME), which strongly influences CAR treatment responsiveness. Therefore, we here provide a systematic overview of CAR-based therapeutic targets in pHGG entities, focusing on clinical trials and preclinical research, and comparing them to adult glioma. We conclude that target expression, TIME and CAR treatment-related toxicities vary across pHGG entities and differ from adult HGG, which suggests the need for more tailored immunotherapeutic CAR approaches in pHGG. Overall, we provide a target roadmap for future development of CAR-based therapeutic strategies for pediatric HGG patients, who are in desperate need for novel therapies. Graphical The number of potential CAR-based therapeutic targets for glioblastoma and pHGG. CAR: Chimeric antigen receptor; pHGG: pediatric high-grade glioma; DHG: H3 G34-mutant diffuse hemispheric glioma; DMG: H3 K27-altered diffuse midline glioma; PFA: posterior fossa ependymoma type A. Image was created in Biorender.com .

31 March 2023
Verified
Other
Open access
MMMichaël H. Meel
Michaël H. Meel
MGMark Cornelis de Gooijer
Mark Cornelis de Gooijer
DMDennis Serge Metselaar
Dennis Serge Metselaar
ASA. Charlotte P. Sewing
A. Charlotte P. Sewing
KZKenn Zwaan
Kenn Zwaan
EHEsther Hulleman
Esther Hulleman
Sequences of shRNA constructs used in the present study.